CV
Technologies Inc., maker of COLD-fX®, today released
its financial and operating results for the second quarter
of fiscal 2006 which includes the three month period ending
March 31, 2006.
CV
Technologies Inc. announced today that it has obtained
clearance from the U.S. Food and Drug Administration (FDA)
to market its Canadian cold and flu remedy COLD-fX®
in the United States. The unique patented active ingredient
of COLD-fX (CVT-E002) has been accepted by the FDA as
a New Dietary Ingredient (NDI).
CV
Technologies Inc. announced today that it has received
approval to begin trading of its common shares on the
Toronto Stock Exchange beginning Wednesday, March 22,
2006. The Company will continue to trade under the symbol
(CVQ).
CV Technologies Inc. today announces its plans for entry into the United States. Company President, CEO and Chief Scientific Officer Dr. Jacqueline Shan will unveil the Company's future U.S. growth strategy at its annual general meeting in Edmonton this afternoon.
CV Technologies Inc., maker of COLD-fX®, today released its financial and operating results for the first quarter of fiscal 2006 which includes the three months of October, November and December, 2005. The quarter was highlighted by record sales and earnings.
CV Technologies Inc. (TSX VENTURE:CVQ) - maker of COLD-fX® - announced today that the Company's application for listing of its common shares on the Toronto Stock Exchange has been conditionally approved.
CV Technologies Inc., maker of COLD-fX®, today reported preliminary net sales figures of $18.9 million for the first quarter of fiscal 2006. This represents an increase of $7.6 million over first quarter sales of $11.3 million for the same period last year.
CV Technologies Inc. today issued a shareholder’s advisory on Company happenings of note, including a report from ACNielsen’s confirming that COLD-fX® remains the top selling cold and flu remedy in Canada.
CV Technologies Inc. (CVT) was today named the top ranked company in the 2005 TSX Venture 50™, the first ever ranking of Canada's top emerging public companies listed on the TSX Venture Exchange.
CV Technologies Inc. (CVT) today released its financial statement for fiscal 2005 showing record sales and profits. The Company - maker of COLD-fX® - ended the year with net sales of $31.9 million - an increase of 398% over the $6.4 million achieved the previous year.
The Canadian Medical Association Journal - regarded as one of the five top general medical journals in the world - will tomorrow publish a landmark double-blind, placebo-controlled study on the prevention and relief of upper respiratory infections.
Les Canadiens have relied on COLD-fX® for the past five seasons to help protect the team during cold and flu season. Now, based on COLD-fX®'s effectiveness at keeping the team healthy, and in celebration of the Company's newly announced expansion in Quebec, COLD-fX® moves officially onto the blue, white and red bench, as the trusted cold and flu remedy of the Montreal Canadiens.
CV Technologies Inc. (CVT) today issued a shareholder's advisory on company happenings of note which include the following:
Preliminary gross sales figures for fiscal 2005 (ending September 30) of $33 million. CVT closed its fiscal year with fourth quarter (July, August, September) preliminary gross sales of $8 million.
CV Technologies Inc. (CVT) today announced that 720 healthy seniors in Edmonton, Toronto and Vancouver will be involved in a national trial designed to protect them from influenza and cold viral infections. Edmonton's Medical Officer of Health will head the national study.
CV Technologies Inc. (CVT) today launched CELL-fX® - a new scientifically proven natural therapeutic for bone and joint pain approved by Health Canada. Four CFL teams today announced that they'll be using it to treat player injuries this season.
CV Technologies Inc. (CVT) today released its financial and operating results for the third quarter of fiscal 2005. The Company reported net sales of $2.8 million compared to $1.2 million for the same period last year, a quarter over quarter increase of 131%. Year to date the net sales were $24.7 million ($4.1 million in 2004).
CV Technologies Inc. (CVT) today released its net sales and profit figures for the second quarter of 2005 which showed sales of $10.5 million and a profit of $3.1 million. This represents an 804% increase in sales over the comparable period a year earlier. Profits increased by $3.4 million from a loss of $0.3 million for the same quarter in fiscal 2004.
Legal Terms & Conditions
